Today's Focus:

China Life Insurance (02628.HK): It is expected that the net income attributable to the mother in the first three quarters will be between 101.135 billion and 108.767 billion yuan, a year-on-year increase of 165% to 185%.

China Life Insurance (02628.HK) released a performance pre-increase announcement for the first three quarters of 2024. According to the company's preliminary calculations, it is estimated that under enterprise accounting standards, the company's net income attributable to the parent company shareholders in the first three quarters of 2024 will be approximately 101.135 billion yuan to 108.767 billion yuan, an increase of approximately 62.971 billion yuan to 70.603 billion yuan compared to the same period in 2023, representing a year-on-year growth of about 165% to 185%.

The announcement stated that the company adheres to the principle of asset-liability matching and long-term, value, and prudent investment philosophies, seizes market opportunities for cross-cycle allocation, and continues to promote the optimization of equity investment structure. In the third quarter of 2024, the stock market significantly rebounded, leading to a substantial year-on-year increase in the company's investment income.

Important event

Fangyuan International (02516.HK): Won the bid for the Alibaba International Station East China Center warehouse business.

Chinasoft Int'l (00354.HK): Multiple Hongmeng projects launched to accelerate business innovation in the financial sector.

Performance of Financial Report:

Oiwahpawn (01319.HK) expects a 30% to 50% decrease in mid-term net income.

Operating Data:

China Pacific Insurance (02601.HK): China Pacific Life's accumulated original insurance premium income in the first three quarters was 209.593 billion yuan, a 2.4% year-on-year increase.

China Coal Energy (01898.HK) sold 24.61 million tons of commodity coal in September, a year-on-year increase of 18.5%.

Qinhuangdao Port (03369.HK): Total throughput of goods in the first three quarters was 0.3 billion tons, a 1.47% year-on-year increase.

Medical Innovation:

United Lab (03933.HK): Amoxicillin granules passed consistency evaluation.

Kintor Pharmaceutical-B (09939.HK): Completion of the first subject entry in a pivotal clinical trial for KX-826 solution 1.0% in treating androgenetic alopecia in Chinese adult males.

Kangrun Biotech-B (06922.HK): Signed a research cooperation agreement with the Guangzhou National Laboratory and the First Affiliated Hospital of Guangzhou Medical University.

Acquisitions and Disposals:

cnnc int'l (02302.HK) plans to sell all equity of cnnc int'l (Hong Kong) for 0.167 billion Hong Kong dollars.

【Increase and Decrease】

China Coal Energy (01898.HK): China Coal increased its shareholding by 6 million A-shares.

Holly Futures (03678.HK): Shareholder Hong Su Industrial passively reduced their shareholding by 1.15%.

Repurchase cancellation.

SUTENG JUCHUANG (02498.HK) intends to further repurchase shares not exceeding 0.3 billion Hong Kong dollars.

hsbc holdings (00005.HK) spent 0.107 billion Hong Kong dollars on repurchasing 1.5788 million shares on October 15th.

Stanchart (02888.HK) spent 13.65 million British pounds to repurchase 1.643 million shares on October 15th.

AIA (01299.HK) spent HKD 62.0181 million on October 16 to repurchase 0.9778 million shares.

Kuaishou-W (01024.HK) spent 21.765 million Hong Kong dollars on repurchasing 0.469 million shares on October 16th.

Swire Pacific A (00019.HK) spent HKD 18.89 million on October 16 to repurchase 0.295 million shares.

Yum China (09987.HK) spent USD 2.4 million on October 15 to repurchase 0.054 million shares.

CCT Fortis (00138.HK) canceled 4.686 million shares to buy back shares on October 16.